Ogeda S.A.

Plus: FDA clears Astellas’ therapy for hot flashes updates from Cullgen and SFJ-Serb

Plus: FDA reviewing Onpattro for larger ATTR indication; EU gets first hemophilia B gene therapy; and updates from Merck, Pfizer and more

As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities

Astellas’ bet on women’s health company Ogeda is paying off with a pair of positive Phase III readouts for its first-in-class, non-hormonal menopause therapy. Astellas Pharma Inc.

How Newton hopes to facilitate deals between Europe, Japan with €200 million fund

Vesalius targeting European late-stage life science companies with third fund